← Back to Search

Light Therapy

Light Therapy for Alzheimer's Disease

N/A

Recruiting

Led By Mariana G Figueiro, PhD

Research Sponsored by Icahn School of Medicine at Mount Sinai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Mild Alzheimer's Disease

Mild cognitive impairment

Must not have

Insulin-dependent diabetes

Macular degeneration

Timeline

Screening 3 weeks

Treatment Varies

Follow Up done at baseline, week 13, 25 and 48

Summary

This trial will study the long-term effects of a light treatment on cognition, sleep and metabolism in patients with MCI or mild ADRD.

Who is the study for?

This trial is for people with mild cognitive impairment or early Alzheimer's who have trouble sleeping and live at home. It's not suitable for those who are blind, need insulin for diabetes, have severe vision loss from macular degeneration, or serious sleep apnea.

What is being tested?

The study is looking into how a special lighting setup in the home can affect thinking abilities, sleep quality, and body metabolism over time in individuals with mild memory problems or early Alzheimer's disease.

What are the potential side effects?

Since this trial involves a lighting intervention, side effects may be minimal but could include discomfort due to changes in light exposure which might affect sleep patterns or eye strain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with mild Alzheimer's Disease.

Select...

I have mild memory or thinking problems.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I use insulin to manage my diabetes.

Select...

I have macular degeneration.

Select...

I have been diagnosed with severe sleep apnea.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ done at baseline, week 13, 25 and 48

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~done at baseline, week 13, 25 and 48

This trial's timeline: 3 weeks for screening, Varies for treatment, and done at baseline, week 13, 25 and 48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Cognition

Depression

Metabolic control

+1 more

Secondary study objectives

Light measurements

Melatonin Levels

Sleep disturbance using actigraphy

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Active Lighting InterventionActive Control1 Intervention

The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater). The lighting intervention will be in place for 24 weeks

Group II: Placebo Lighting InterventionPlacebo Group1 Intervention

The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.

0 / 5Eligibility criteria met